Neonatal Abstinence Syndrome Advisory Committee

Annual Report to the General Assembly

3/31/2017
Contents
Legislative Mandate .............................................................................................................. 3
Background .......................................................................................................................... 5
   Opioid Use and Abuse ..................................................................................................... 5
      Overall Population ..................................................................................................... 5
      Women of Reproductive Age ..................................................................................... 6
      Pregnant Women ....................................................................................................... 7
Neonatal Abstinence Syndrome (NAS) ............................................................................... 7
   Descriptive Epidemiology .............................................................................................. 7
   Impact of NAS .............................................................................................................. 8
   Relation of NAS to Opioid Use .................................................................................... 8
NAS Advisory Committee ................................................................................................. 9
   Activities ...................................................................................................................... 9
   Recommendations ...................................................................................................... 10
Data Analysis in Illinois .................................................................................................... 10
   Hospital Discharge Data .............................................................................................. 10
   Adverse Pregnancy Outcome Reporting System (APORS) .......................................... 11
   Medicaid Claims Data ................................................................................................. 12
   Data Summary .............................................................................................................. 13
Conclusion .......................................................................................................................... 14
Legislative Mandate

In 2015 the Department of Public Health Powers and Duties Law (section 2310-677) created the Neonatal Abstinence Syndrome (NAS) Advisory Committee. The committee, chaired by the Director of the Illinois Department of Public Health (IDPH), or his designee, is charged with advising and assisting IDPH to:

1. Develop an appropriate standard clinical definition of "NAS";
2. Develop a uniform process of identifying NAS;
3. Develop protocols for training hospital personnel in implementing an appropriate and uniform process for identifying and treating NAS;
4. Identify and develop options for reporting NAS data to IDPH by using existing or new data reporting options; and
5. Make recommendations to IDPH on evidence-based guidelines and programs to improve the outcomes of pregnancies with respect to NAS.

The Advisory Committee shall provide an annual report of its activities and recommendations to the IDPH Director, the General Assembly, and the Governor by March 31 of each year, beginning in 2016. The final report shall be submitted by March 31, 2019.
Background

Neonatal Abstinence Syndrome (NAS) was first identified among neonates whose mothers most commonly used heroin or were on methadone maintenance, in the 1970s. NAS refers to the collection of signs and symptoms that occur when a newborn prenatally exposed to opiates experiences opioid withdrawal. The syndrome is primarily characterized by irritability, tremors, feeding problems, vomiting, diarrhea, sweating, and, in some cases, seizures.  

According to Dr. Ira Chasnoff, in a 2015 editorial for the *Journal of Perinatology*, the incidence of NAS has varied over the past several decades, usually correlated with the ebbs and flows of heroin use in the general populations. Chasnoff further notes that the current increase in NAS is associated with a diverse spectrum of pregnant women’s use of opiates, including heroin addiction, polydrug use, prescribed and illegal prescription opioid use, and methadone or buprenorphine assisted treatment (MAT).  

Opioid Use and Abuse

Overall Population

In 2014, about 0.3% of the population 12 and older used heroin nationally; this represents a significant increase over prior years. Heroin use remains the highest among 18-25 year olds, with 0.8% of this population having reported using heroin in 2014. Heroin use increased the most among this age group between 2002 and 2014.  

Approximately 1.6% of the United States population 12 and older used prescription pain relievers for non-medical reasons in 2014. However, non-medical use of prescription pain relievers decreased over time, down from 1.9%-2.1%, seen during 2002-2010. Non-medical use of prescription pain relievers is
most common among 18-25 year olds (2.8% in 2014), but this age group also experienced the largest recent decreases in non-medical prescription pain reliever use.\textsuperscript{3}

It is estimated that approximately 20% of patients presenting to physician offices for pain symptoms or pain-related diagnoses receive an opioid prescription. In 2012, health care providers in the United States wrote 259 million prescriptions for opioid pain medication, and per capita opioid prescriptions increased 7.3% from 2007 to 2012.\textsuperscript{2} Another study used pharmacy data to highlight the widespread state-by-state variation in the prescribing of opioid medications. Illinois had one of the lowest per capita opioid prescribing rates in the United States, ranking 43\textsuperscript{rd} out of the 50 states and District of Colombia, at 67.9 prescriptions per 100 persons (the national rate was 82.5 prescriptions per 100 persons). Additionally, Illinois had the second lowest prescribing rate for long-acting/extended-release opioids and for high-dose opioid pain relievers.\textsuperscript{3}

In March 2016, the Centers for Disease Control and Prevention (CDC) issued new guidelines related to the prescribing of opioids for primary care providers who treat patients with chronic pain in outpatient settings. These guidelines provide evidence-based recommendations for three topics: 1) determining when to initiate or continue opioids for chronic pain; 2) opioid selection, dosage, duration, follow-up, and discontinuation; and 3) assessing risk and harms of opioid use.\textsuperscript{2}

In 2013, there were approximately 11,900 Illinoisans enrolled in opioid treatment programs receiving methadone and 1,200 receiving buprenorphine. The number of people receiving methadone in treatment programs has remained fairly consistent since 2009, but the number of people receiving buprenorphine more than doubled between 2009 and 2012.\textsuperscript{4}

**Women of Reproductive Age**

A study of 2008-2012 health insurance claims among women of reproductive age (15-44 years old) showed that approximately 27.7% of privately-insured women and 39.4% of Medicaid-enrolled women filled a
prescription for an opioid from an outpatient pharmacy each year. For both insurance groups, the most commonly prescribed opioids were: hydrocodone, codeine, and oxycodone. Of women who filled an opioid prescription, the average number of per capita opioid prescriptions filled per year was 2.6 prescriptions for privately insured women and 4.3 prescriptions for Medicaid-enrolled women.

Older women (30-44) were more likely to have filled an opioid prescription during the last year for both insurance groups. Among Medicaid-enrolled women, Non-Hispanic white women were the most likely to fill an opioid prescription (46.4%, vs. 35.2% among Non-Hispanic black women and 33.6% among Hispanic women). Race/ethnicity information was not available for the privately-insured women.5

**Pregnant Women**

According to Illinois Discharge Data, from 2011 through 2015, the “recorded” rate of maternal antenatal opioid use among deliveries increased by 5.9% per quarter from six per 1,000 deliveries in the first quarter of 2011 to over 15 per 1,000 deliveries in fourth quarter 2015.

**Neonatal Abstinence Syndrome (NAS)**

**Descriptive Epidemiology**

National surveillance studies have demonstrated that the incidence of neonatal abstinence syndrome (NAS) increased from 1.2 per 1,000 hospital births in 2000 to 5.8 per 1,000 births in 2012 – a 70% increase in only 4 years.7,9

According to Illinois Hospital Discharge Data, the rate of Neonatal Abstinence Syndrome increased by 2.2% per quarter from 2011-2015 (2.13 per 1,000 births in first quarter 2011 to 2.87 per quarter in fourth quarter 2015). Further analysis of the data from 2015 revealed that although the overall rate of babies born with NAS was 2.51 per 1,000, the rate for Non-Hispanic White infants (3.55 per 1,000 births) was over three times the rate for Hispanic infants (1.11 per 1,000 births).
**Impact of NAS**

Infants with NAS are more likely to have other adverse outcomes and complications at birth, including: low birth weight, respiratory problems, jaundice, feeding difficulties, seizures, and sepsis.\(^8,9\) Infants with NAS have longer hospital stays and incur higher hospital charges than infants without NAS. A national study of 2012 data showed that NAS infants had a mean hospital stay of about 17 days, compared to two days for an uncomplicated term infant. The average hospital charges for an NAS infant were $66,700 in 2012, compared to about $3,500 for an uncomplicated term infant.\(^8\) Additionally, infants with NAS are 150% more likely than uncomplicated term infants to be readmitted to the hospital within 30 days after birth.\(^9\)

The burden on neonatal intensive care units (NICUs) due to NAS has increased over time. In one study of hospital NICUs throughout the United States, the percentage of total NICU days attributed to infants with NAS increased five-fold - from 0.6% in 2004 to 4.0% in 2013. They also demonstrated that length of stay for NAS infants significantly increased by about six days between 2004 and 2013.\(^10\)

**Relation of NAS to Opioid Use**

A Medicaid-enrolled pregnant women study, conducted in Tennessee, found the risk of NAS increased when a woman was prescribed any opioids during pregnancy. Among women with no prescribed opioids, 0.5% of their infants developed NAS (presumably due to illicit use of opioids). If a woman was prescribed short-acting, long-acting, or maintenance opioids during pregnancy, the percent of infants with NAS respectively increased to 1.4%, 14.7%, and 29.3%. In addition, this study found that NAS risk was increased even more when opioid use was combined with tobacco or selective serotonin reuptake inhibitors (SSRI) during pregnancy.\(^7\)

Another study in Tennessee collected and examined detailed case information for infants diagnosed with NAS. In 2013, 42% of NAS cases involved maternal use of prescription opioids during pregnancy,
22% involved both exposure to a medication prescribed by a health care provider and an illicit/diverted drug, and 33% involved exposure to illicit/diverted substances only. In addition to the clinical signs of NAS, over 98% of cases had at least one of the following: positive maternal screen, positive neonatal drug screen, or history of maternal substance use.\textsuperscript{11}

The summaries in the previous sections mostly rely on studies using national data; very little Illinois-specific information is available from these published reports and studies.

**NAS Advisory Committee**

**Activities**

The Neonatal Abstinence Advisory Committee (Appendix I) has been established in accordance with the Act. The committee met three times in the year since the March 2016 report. Following are highlights from the meetings:

1. The NAS Advisory Council discussed NAS from a national perspective, including the legislative activities occurring in other states regarding NAS
2. Met with the Illinois Department of Children and Family Services to (DCFS) to identify the current requirements regarding mandated reporting of infants born with NAS
3. Received presentations on Illinois data related to NAS to identify potential biases in screening and diagnosis of NAS
4. Identified a need for non-voting members representative of Illinois’ myriad demographics, including rural and urban areas and a focus group or panel of women with a history of substance use to provide input on various perspectives of the issue
5. Determined that in order to meet their second charge, which is to develop a uniform process for identifying NAS, they will need to consider-criteria for screening, potential for universal drug screening-remaining cognizant that this may serve as a deterrent to maternal patient in compliance with prenatal care; advantages and disadvantages of using Prescription Monitoring Program (PMP) in screening assessment
6. Researched and reported on the work being done in other states around Neonatal Abstinence Syndrome

**Recommendation**

The Neonatal Abstinence Committee made the following recommendation:

**Charge 1:** Develop an appropriate standard clinical definition of NAS
Neonatal Abstinence Syndrome refers to the collection of signs and symptoms that occur when a newborn prenatally exposed to prescribed, diverted, or illicit opiates experiences opioid withdrawal. This syndrome is primarily characterized by irritability, tremors, feeding problems, vomiting, diarrhea, sweating, and, in some cases, seizures.

Data Analysis in Illinois

To understand the trends and opportunities for prevention in Illinois better, the state conducted the following analyses.

Hospital Discharge Data

Hospital discharge data are administrative/billing records available for all hospitalizations in Illinois facilities, including newborn hospital stays. This dataset includes many fields where diagnosis codes relevant to the hospital stay can be recorded. NAS is identifiable via the presence of the ICD-9 (International Classification of Diseases, version 9) diagnosis code 779.4 in any diagnosis field on the newborn’s discharge record. According to Illinois Hospital Discharge Data, the rate of Neonatal Abstinence Syndrome increased by 2.2% per quarter from 2011-2015 - 2.13 per 1,000 births in first quarter 2011 to 2.87 per quarter in fourth quarter 2015.

It should be noted that discharge data may underestimate the true NAS incidence rates. A study in Florida showed that linking supplemental data sources such as NICU admission logs and inpatient pharmacy data to hospital discharge data increased NAS case identification by 30%. Supplementing discharge data with data from other sources would likely increase the number of identified NAS cases in Illinois.
Adverse Pregnancy Outcome Reporting System (APORS)

APORS is the IDPH surveillance system for a variety of adverse outcome in infants, including: birth defects, very low birth weight, positive drug screens, and drug withdrawal symptoms. The main purpose of APORS is to identify high-risk infants and to refer these children and their families to the Illinois Department of Human Services’ High-Risk Infant Follow-up Program, which provides case management services until the infant is two years old.

There are two categories of high-risk infants reported to APORS that are relevant to NAS. The first is the identification of infants with any positive drug toxicity tests. These tests can also be classified by type of drug. A limitation to the data on these cases is that APORS cannot be used to produce prevalence estimates of prenatal drug exposure because the total number of infants tested for drug exposure is not known. A 2001 APORS report described how the data on drug exposure in pregnancy from this surveillance system are likely to be very incomplete and potentially biased.\(^{13}\) There is wide variation across hospitals in how many and which infants are tested, with some hospitals testing every infant and some hospitals testing only infants perceived to be at higher risk of drug exposure. In hospitals without universal testing, there is likely to be an underestimate of prenatal drug exposure because some exposed infants might not be tested. Additionally, there may be testing bias related to which mothers/infants are screened for drug use, which could distort the observed demographic and geographic patterns in drug exposure. The reportable data on positive drug tests in newborns is useful for referring high-risk infants to follow-up case management services, but it is not likely to be useful for population-based surveillance of prenatal drug exposure.

The second relevant category of high-risk infants reported to APORS is infants with drug withdrawal symptoms, or an NAS diagnosis. Any infants with clinical signs of drug toxicity or exposure are reported by hospitals to APORS for follow-up services. Because drug withdrawal is based on symptoms of the
infant during the delivery and the subsequent hospitalization, it should be more complete and unbiased than the drug test data.

Following is a table of APORS data on infants reported as drug exposed, reported withdrawal and reported withdrawal rates from 7/1/13 to 8/22/16.

<table>
<thead>
<tr>
<th>Drug Exposed Infants</th>
<th>Reported Withdrawal</th>
<th>Reported Withdrawal Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioids</td>
<td>1,449</td>
<td>152</td>
</tr>
<tr>
<td>Cocaine</td>
<td>753</td>
<td>47</td>
</tr>
<tr>
<td>Mixed, Others, Unknown</td>
<td>1,578</td>
<td>309</td>
</tr>
<tr>
<td>Total</td>
<td>3,026</td>
<td>476</td>
</tr>
</tbody>
</table>

Following is a comparison of APORS data to hospital discharge data, this may provide the most accurate count of NAS cases in Illinois.

<table>
<thead>
<tr>
<th>Dates</th>
<th>APORS: # of infants who were opioid exposed</th>
<th>APORS: # of infants with drug withdrawal</th>
<th>HDD: # of infants with NAS ICD codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013 Quarter 3 and 4</td>
<td>252</td>
<td>113</td>
<td>193</td>
</tr>
<tr>
<td>2014</td>
<td>454</td>
<td>151</td>
<td>341</td>
</tr>
<tr>
<td>2015</td>
<td>504</td>
<td>147</td>
<td>373</td>
</tr>
</tbody>
</table>

Medicaid Claims Data

Several studies have used Medicaid claims data to examine prescriptions for opioids among women of reproductive age and pregnant women. Pharmacy claims data from the Illinois Department of Healthcare and Family Services could be used for several purposes. The first would be for surveillance of prescribing patterns and trends over time. Secondly, Medicaid claims data could be used to develop a
quality metric that monitors appropriate vs. inappropriate prescribing patterns for women, and particularly for pregnant women. There are not currently any such quality measures endorsed by national quality or Medicaid organizations, but review of the very new CDC guidelines on opioid prescribing\textsuperscript{2} may enable their development. Finally, Medicaid data could be linked to hospital discharge data and/or APORS records to examine the prescription history of women whose infants developed NAS. This may help to provide more information about the prenatal exposure history for NAS infants and to describe the risk associated with various prescribing patterns.

In any of these scenarios, the data would only be relevant to women enrolled in Medicaid, which covers about half of the births in Illinois. However, given that a national study found that over 80\% of NAS cases occurred to infants of Medicaid-enrolled women,\textsuperscript{9} this limitation may not be particularly concerning.

**Data Summary**

While current data on NAS and opioid use are not readily available in published reports or scientific literature, Illinois has used existing data sources to identify NAS cases and to examine opioid prescribing among women. There are not population-based data sources available to estimate the prevalence of heroin or illicit prescription opioid use among Illinois women.

There is also an opportunity to examine the current data collection systems and to determine whether additional information on NAS cases should be collected or current surveillance systems augmented. For example, APORS could be supported to conduct chart reviews to verify NAS diagnosis and to collect additional information on drug exposure during pregnancy. The linkage of multiple data sets would also likely increase the case ascertainment of NAS and provide more accurate estimates of NAS incidence among Illinois infants.

**Conclusion**
The increase in neonatal abstinence syndrome, resulting from the increased use/abuse of opioids by pregnant women, make the work of the NAS Advisory Committee critical to ensuring healthy outcomes for Illinois’ most vulnerable population. The Committee will continue the process of reviewing state specific available data and expects to be making recommendations in the future on ways to improve the outcomes in regards to NAS.


